File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life

TitleLeveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life
Authors
KeywordsAllergy
Beta-lactam
COVID-19 vaccine
Delabelling
Drug allergy
Effectiveness
Health-related quality of life
Issue Date19-Mar-2025
PublisherElsevier
Citation
Vaccine, 2025, v. 50 How to Cite?
AbstractBackground: Concerns of potential drug/vaccine-associated allergies significantly impact vaccine safety and hesitancy. Delabelling of incorrect drug allergy in the general public was previously impeded by limited access to allergist services, especially among less frequent healthcare utilisers in the community. COVID-19 vaccine allergy evaluation services have enabled individuals (mis)labelled with allergies to receive vaccinations safely and have provided opportunities to expand drug allergy delabeling access. We investigated the effectiveness of this coincident drug allergy delabelling and its impact on health-related quality of life (HRQoL). Methods: We recruited individuals labelled with drug allergies attending for COVID-19 vaccine evaluation in Hong Kong between 2021 and 2022. Demographics, comorbidities, drug allergy labels, COVID-19 vaccination and infection outcomes, as well as coincident delabelling rates were analysed. HRQoL was measured before and after evaluation in a subgroup of individuals. Results: Among 652 individuals, 1456 drug allergy labels were identified, with anti-infectives being the most common (606, 41.6 %). Beta-lactam antibiotics accounted for 55.1 % (334). Almost all individuals (99.4 %) safely proceeded with COVID-19 vaccinations, with an increased number of doses conferring better protection. 228 (35.0 %) individuals underwent drug allergy investigations, with coincident drug allergy delabelling successful in 223 (97.8 %), removing 317 (21.8 %) incorrect labels, of which 173 (51.8 %) were beta-lactams. Subgroup analysis showed improved serial health-related quality of life following delabelling (DrHy-Q 45.0 vs 33.3, p < 0.001). Conclusion: Services evaluating COVID-19 vaccine allergies have not only empowered individuals labelled with drug allergy to receive vaccinations safely, but have also enhanced access to drug allergy delabeling services for the general public.
Persistent Identifierhttp://hdl.handle.net/10722/357549
ISSN
2023 Impact Factor: 4.5
2023 SCImago Journal Rankings: 1.342
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKan, Andy K.C.-
dc.contributor.authorMak, Hugo W.F.-
dc.contributor.authorChiang, Valerie-
dc.contributor.authorYim, Jackie S.H.-
dc.contributor.authorShi, Weihong-
dc.contributor.authorLi, Philip H.-
dc.date.accessioned2025-07-22T03:13:26Z-
dc.date.available2025-07-22T03:13:26Z-
dc.date.issued2025-03-19-
dc.identifier.citationVaccine, 2025, v. 50-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/357549-
dc.description.abstractBackground: Concerns of potential drug/vaccine-associated allergies significantly impact vaccine safety and hesitancy. Delabelling of incorrect drug allergy in the general public was previously impeded by limited access to allergist services, especially among less frequent healthcare utilisers in the community. COVID-19 vaccine allergy evaluation services have enabled individuals (mis)labelled with allergies to receive vaccinations safely and have provided opportunities to expand drug allergy delabeling access. We investigated the effectiveness of this coincident drug allergy delabelling and its impact on health-related quality of life (HRQoL). Methods: We recruited individuals labelled with drug allergies attending for COVID-19 vaccine evaluation in Hong Kong between 2021 and 2022. Demographics, comorbidities, drug allergy labels, COVID-19 vaccination and infection outcomes, as well as coincident delabelling rates were analysed. HRQoL was measured before and after evaluation in a subgroup of individuals. Results: Among 652 individuals, 1456 drug allergy labels were identified, with anti-infectives being the most common (606, 41.6 %). Beta-lactam antibiotics accounted for 55.1 % (334). Almost all individuals (99.4 %) safely proceeded with COVID-19 vaccinations, with an increased number of doses conferring better protection. 228 (35.0 %) individuals underwent drug allergy investigations, with coincident drug allergy delabelling successful in 223 (97.8 %), removing 317 (21.8 %) incorrect labels, of which 173 (51.8 %) were beta-lactams. Subgroup analysis showed improved serial health-related quality of life following delabelling (DrHy-Q 45.0 vs 33.3, p < 0.001). Conclusion: Services evaluating COVID-19 vaccine allergies have not only empowered individuals labelled with drug allergy to receive vaccinations safely, but have also enhanced access to drug allergy delabeling services for the general public.-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofVaccine-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectAllergy-
dc.subjectBeta-lactam-
dc.subjectCOVID-19 vaccine-
dc.subjectDelabelling-
dc.subjectDrug allergy-
dc.subjectEffectiveness-
dc.subjectHealth-related quality of life-
dc.titleLeveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life-
dc.typeArticle-
dc.identifier.doi10.1016/j.vaccine.2025.126849-
dc.identifier.pmid39914252-
dc.identifier.scopuseid_2-s2.0-85216833793-
dc.identifier.volume50-
dc.identifier.eissn1873-2518-
dc.identifier.isiWOS:001424072400001-
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats